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The sodium dependent reduced folate carrier (Rfc1; Slc19a1) provides the major route for cellular uptake of reduced folates and antifolate
drugs such as methotrexate (MTX) into various tissues. Despite its essential role in folate homeostasis and cancer treatment, little is known about
Rfc1 regulation. A barbiturate recognition box, which as yet has only been found in the promoter region of xenobiotic metabolizing enzymes,
particularly those of the CYP450 enzyme family, was predicted in the 5′ untranslated region of rat rfc1 cDNA. We have therefore investigated the
regulation of Rfc1 by phenobarbital (PB)-type CYP450 inducers on the functional, transcriptional and translational level in a suitable in vitro
model for rat liver. A decrease of >75% in substrate uptake was observed following treatment (48 h) with 1–10 times therapeutic plasma
concentrations of PB-type CYP450 inducers like PB, carbamazepine, chlorpromazine, clotrimazole and with 0.1–1 ng/ml of the constitutive
androstane receptor agonist TCPOBOP. This was not associated with reduced mRNA and protein levels. Further mechanistic investigations
revealed that short-term treatment (2 h) of cells with protein phosphatase 1/2A inhibitor okadaic acid (80.5 ng/ml) and proteinkinase C inducer
phorbol 12-myristate 13-acetate (PMA; 0.62 μg/ml) almost abolished Rfc1 mediated MTX uptake. Finally, the reduction in Rfc1 activity caused
by PB, TCPOBOP and PMA was reversed by simultaneous incubation with the specific PKC inhibitor bisindolylmaleimide (BIM; 21 ng/ml).
These results demonstrate that clinically relevant concentrations of PB-type CYP450 inducers cause a significant PKC-dependent reduction in
Rfc1 uptake activity at the posttranscriptional level.
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liver, kidneys and other tissues [1,2]. The internalization of
folates from dietary sources is vital for the biosynthesis of
nucleic acids and proteins as mammalian cells do not possess
the ability to synthesize these cofactors de novo [3]. The folate
antagonist MTX, another typical Rfc1 substrate, is an essential
component in the treatment of malignancies like acute
lymphoblastic leukemias (ALL; [4]) and autoimmune diseases
such as rheumatoid arthritis [5].
Both human RFC1 [6] and rodent Rfc1 [7–10] cDNA clones
have been isolated and encode a carrier protein with 12 putative
transmembrane domains which is expressed ubiquitously but to
different levels in all tissues and a number of tumor cells
[1,9,10]. In liver and kidneys, RFC1/Rfc1 is present at the
basolateral membrane whereas in the intestinal tract and choroid
plexus the transporter is located on the apical membrane
[1,11,12]. Several studies confirm that RFC1/Rfc1 provides a
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folates and antifolates (Km ∼1–10 μM) which is sodium-
dependent at neutral pH [1,13–15].
In contrast to the well-characterized functional properties of
this carrier and in spite of its essential role in folate absorption
and MTX cancer chemotherapy, comparatively little is known
about the regulation of RFC1/Rfc1 in mammalian cells. Recent
studies point out that different transcription factors including
members of the Sp family and the bZip superfamily or usage of
alternate promoters/non-coding exons play an important role in
the tissue-specific RFC1/Rfc1 expression and function [1], e.g.
in response to different requirements for folates. In rat
hepatocytes, the 5′ untranslated region of the carrier mRNA
exhibits, amongst other regulatory elements, a predicted
barbiturate recognition box [10]. Until now, this sequence has
only been reported in the promoter region of xenobiotic
metabolizing enzymes, particularly those of the cytochrome
(CYP) P450 enzyme family [16]. Interestingly, clinical studies
suggest the possibility that treatment with the phenobarbital
(PB)-type CYP450 inducers PB and carbamazepine (CBZ) may
cause a significant reduction in intracellular MTX accumulation
associated with lower efficacy of chemotherapy [17,18]. This
observation could not be easily attributed to CYP450 enzyme
induction as metabolism of MTX is mediated by hepatocellular
aldehyde oxidase and folylpolyglutamate synthetase [4].
Several reports demonstrated that carrier proteins of the
ATP-binding cassette (Abc)-superfamily including the efflux
transporter multidrug resistance-associated protein2 (MRP2/
Mrp2; ABCC2/Abcc2) are co-ordinately regulated with phase I
and II xenobiotic metabolizing enzymes via nuclear receptors
such as the “constitutive androstane receptor (CAR, NR1I3)”
[19]. CAR is characteristically stimulated either directly by the
pesticide contaminant 1,4-bis[2-(3,5-dichloro-pyridyloxy)]ben-
zene (TCPOBOP) [20] or, as has been suggested by others [16],
by PB-type CYP450 inducers. Upon activation, CAR is
translocated from the cytoplasm into the nucleus and as a
heterodimer with the retinoid X receptor (RXR) binds to the
“phenobarbital-responsive enhancer module (PBREM)” within
the promoter region of target genes and regulates their gene
expression [16,19].
Therefore, the aim of this study was to systematically
examine the regulation of Rfc1 by PB-type CYP450 inducers as
well as the CAR agonist TCPOBOP on the functional,
transcriptional, and translational level in the rat hepatocytoma
fusion cell line HPCT-1E3. Furthermore, the involvement of the
postulated regulatory elements and the nuclear receptor CAR
should be elucidated. The HPCT-1E3 hybrid cell line provides a
suitable in vitro model for these studies as it shows the
endogenous expression of liver-specific carrier proteins for
organic anions, including Rfc1 [21].2. Materials and methods
2.1. Reagents
All chemicals including media and supplements were obtained from Sigma-
Aldrich (Deisenhofen, Germany) unless stated otherwise.2.2. Cell culture
The rat hepatocytoma cell line HPCT-1E3 was donated by E. Petzinger
(Justus-Liebig-University, Giessen, Germany) and maintained in Dulbecco's
modified Eagle's medium (DMEM; PAA, Coelbe, Germany) containing 10%
(v/v) fetal calf serum (Gibco, Karlsruhe, Germany), 2 mM glutamine (PAA,
Coelbe, Germany), 10 μg/ml insulin, 10 μg/ml inosine and 1.5 μM
dexamethasone as previously published [21].
2.3. Cell proliferation assay
Cytotoxicity of the selected CYP450 inducers PB, CBZ, chlorpromazine
(CPZ), clotrimazole (CTZ) and TCPOBOP as well as of the respective control
substances diazepam, haloperidol and amphotericin B was evaluated using the
WST-1 (4-[3-(4-Iodophenyl)-2-(4-nitro phenyl)-2H -5-tetrazolio]-1,3-benzene
disulfonate) proliferation test (Roche, Penzberg, Germany). Briefly, HPCT-1E3
cells were seeded into 96-well culture plates (33,250 cells/cm2) and incubated
with various concentrations of the respective PB-type inducer or control
substance. After 48 to 60 h incubation, WST-1-reagent (5% [v/v] in
supplemented DMEM) was added and viability of HPCT-1E3 cells was
measured as the increase in total absorption at 540 nm over 30 min using a
microplate reader (Tecan, Crailsheim, Germany). The IC50 values of the selected
compounds were defined as the drug concentration that reduced the absorbance
by 50% and were determined graphically.
2.4. Pre-treatment of HPCT-1E3 cells
For measurements of Rfc1 mediated uptake of fluoresceinated methotrex-
ate (FMTX; Molecular Probes, Eugene, NL) or [3H] methotrexate ([3H] MTX;
specific activity: 6.18×108 kBq/mmol; Moravek Biochemicals, Brea, CA)
96-well culture plates (33,250 cells/cm2) and cell culture dishes with a
diameter of 94 mm (12,700 cells/cm2), respectively, were used. HPCT-1E3
cells were treated with PB (10 or 100 μg/ml), CBZ (3; 9 μg/ml), CPZ (0.035;
0.35 μg/ml), TCPOBOP (0.1; 1 ng/ml), diazepam (1.5; 15 μg/ml), haloperidol
(0.005; 0.05 μg/ml) or amphotericin B (1; 10 μg/ml) in supplemented DMEM
for 48 h as well as with CTZ (0.034; 0.34 μg/ml) over 60 h. Selected
concentrations of the respective PB-type CYP450 inducers and control
substances were chosen to be comparable to the therapeutic plasma level in
humans [22], or to be tenfold, in case of CBZ threefold, higher than the
therapeutic serum level. Medium was changed every 24 h to maintain stable
effective concentrations. Short-term treatment (2 h) of HPCT-1E3 cells with
80.5 ng/ml phosphatase 1/2A (PP 1/2A) inhibitor okadaic acid, 0.62 μg/ml
proteinkinase C (PKC) inducer PMA, 21 ng/ml of the specific PKC inhibitor
bisindolylmaleimide (BIM), 5.1 μg/ml proteinkinase A (PKA) inducer DB-
cAMP and the specific PKA inhibitor H-89 (52 ng/ml) dissolved in culture
medium was performed to investigate the effect of modulators of phos-
phorylation on Rfc1 uptake activity.
2.5. Uptake assays
Measurements of Rfc1 mediated FMTX and [3H]MTX uptake in HPCT-1E3
cells were carried out as described previously [10,21]. In brief, FMTX (10 μM)
was added for 30 min and cells were lysed with 1% SDS in PBS after 2 washing
steps with ice-cold incubation buffer. Sodium-dependent FMTX accumulation
was assayed in a fluorescence microplate reader (485/535 nm) and expressed in
pmol per mg protein. Rfc1 mediated [3H] MTX uptake was generally examined
after cells were harvested and allowed to recover in fresh culture medium for
20 min. In all cases, cell viability was >95% as assessed by trypan blue
exclusion. After cells were washed 3 times in Tyrode buffer or sodium-free
Choline Tyrode buffer, [3H] MTX (5 μM, 2×105 dpm/ml) was added to 1.2 ml
cell suspension. Aliquots (100 μl) were removed at different time points (0.25;
0.75; 1.25; 3; 5; 10; 20 min) and cells were separated by centrifugation through a
silicone oil layer. The pelleted cells were dissolved in 4 M KOH overnight and
the cell-associated radioactivity was measured by liquid scintillation counting
(LS 6500, Beckman, Fullerton, CA). Protein concentration of the cell
suspension was measured using the bicinchoninic acid (BCA) protein assay
(Pierce, Rockford, IL) and the method of Lowry. Finally, Rfc1 activity was
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mg protein. V(influx)-values were calculated by non-linear regression.
2.6. Reporter gene expression assay
Using PCR primers containing a 5′-overhang with KpnI and HindIII
restriction sites, respectively (GGGGTACCGATCCGGCAGTCTGCTGTG and
CCCAAGCTTCGCAGGCTCTTGGCACG, MWG Biotech AG, Ebersberg,
Germany), a fragment corresponding to exon1, intron1 and exon1a of the rat rfc1
gene was amplified from bacmid BAC CH230-9M13 (Children's Hospital
Oakland Research Institute, Oakland, CA). This fragment was cloned into
pSEAP2 (Clontech, Mountain View, CA) by standard techniques. Position and
identity of the insert were confirmed by restriction analysis and sequencing, and
approximately 2 mg of the plasmid pPMTX-SEAP were isolated using the
EndoFree Mega Kit according to the manufacturer's instructions (Qiagen,
Hilden, Germany). Cos-1 and MDCK cells were seeded in 96-well culture plates
(35,000/cm2) and, the following day, transfected with a mixture of 1 μg/ml
plasmid DNA (0.1 μg/well) and 10 μg/ml polyethyleneimine in DMEMover 4 h.
HPCT-1E3 cells were seeded at a density of 70,000/cm2 and transfected with
0.05 μg DNA per well using 3 μl/μg of the transfection reagent GeneJuice
(Novagen, Madison, WI). One day later, the potential inducer was added and
50 μl of the culture supernatant was removed after 24 h for determination of
SEAP activity (Phospha-Light™, Applied Biosystems, Bedford, MA).
2.7. Quantitative RT-PCR of Rfc1 gene expression
Total RNA was prepared from 5×106 HPCT-1E3 cells grown to confluence
using the RNeasy Mini system (Qiagen, Hilden, Germany) according to the
manufacturer's instructions. A 1 μg aliquot of total RNA was used to synthesize
cDNA under standard conditions employing the Omniscricpt RT kit (Qiagen,
Hilden, Germany) with 4 U of reverse transcriptase and 1 μM oligo(dT16-) primer
(MWGBiotech, Ebersberg, Germany). Quantitative PCRof 1μl cDNAwas carried
out using the PCR-Master-Mix S (peqlab, Erlangen, Deutschland) with 1.25 U
taq-DNA-polymerase, 0.25 mM dNTPs, 0.4 pmol of Rfc1 specific sense (5′-CTG-
GTCATCGCG AGTGTCAT-3′) and antisense (5′-GCAATCTGAAAAGTGGC-
AATG-3′) primers and 0.2 pmol of TaqMan probe (5′-FAM-TCCCGGACATCT-
GGGTCTGCTA-BHQ-1-3′) in a total volume of 25 μl. In a parallel reaction, sense
(5′-AGAGGGAATCGTGCGTGAC-3′), antisense (5′-CGATAGTATGA
CCTGACCGT-3′) β-actin primers and a respective TaqMan probe (5′-TexRed-
CACTGGACCTC TTCCTCCC-BHQ-2-3′) were used. Rfc1 and β-actin gene
specific primers andprobesweredesignedusinggenebankentries andPrimerSelect
(DNASTAR Inc., Madison,WI). PCRwas performed over 40 cycles with an initial
denaturation stepof 30 sec at 94 °C followedby annealing andextension at 62 °Cfor
45 sec in a real-time DNA thermal cycler (iCycler™ iQ Detector, Biorad, Munich,
Germany). The amplified cDNAwas quantified on-line using the iCycler™ iQReal
Time Detection System (Biorad, Munich, Germany). Rfc1 mRNA expression
relative to the normalized (β-actin) control level was calculated by the 2−ΔΔCT
method, taking the Rfc1 PCR efficacy into account.
2.8. Quantitative immunocytochemistry of Rfc1 protein
Relative Rfc1 protein levels were assessed by quantitative immunocyto-
chemistry using a specific Rfc1 antiserum generated in our laboratory which is
directed to the C-terminal region of the carrier protein. HPCT-1E3 cells were
seeded into 96-well culture plates (33,250 cells/cm2) and grown for 3 days until
cells displayed a differentiated phenotype. Following treatments, hepatocytoma
cells were washed 2 times with PBS buffer and fixed for 10 min in 4%
paraformaldehyde in PBS buffer (pH 7.4), incubated with 50 mM NH4Cl and
permeabilized using 0.1%TritonX-100 at room temperature (rt). After cells were
incubated in blocking buffer (3% bovine serum albumin in PBS) over night
followed by 3 washing cycles with PBS, primary antibody (1:500) in blocking
buffer was added for 1 h (rt). Cells were rinsed 3 timeswith PBS buffer for 10min
and incubated with HRP-conjugated swine anti-rabbit secondary antibody
(1:2000; Dako Cytomation, Hamburg, Germany) in blocking buffer (rt).
Afterwards, substrate solution consisting of 1 mg/ml tetramethylbenzidine,
50 mM citric acid, 80 mM Na2HPO4 and 0.006% H2O2 was added for 1 h (rt) in
the dark. Finally, the reaction was stopped with 2 N H2SO4 and Rfc1 content wasmeasured spectrophotometrically (OD450) using a microplate reader (Tecan,
Crailsheim, Germany). Control incubations included omission of secondary and/
or primary antibody. Protein was measured using the BCA protein assay and
relative Rfc1 protein levels were expressed relatively to the control level as %
extinction per mg of total protein.
2.9. Statistical analysis
Statistical analysis of all data was carried out using Microsoft Excel software
(Office 2000). Curve fittings were performed by means of SigmaPlot (SPSS
Science, Chicago, IL). Viability of HPCT-1E3 cells, transport activities as well
as Rfc1 gene expression are given as means±SD of at least quadruplicate
measurements. Student's t-test was used to determine the significance of
differences between respective measurements after elimination of outliers with a
G-test. Statistical significance was assumed at P values of ≤0.05.
Standard deviation of sodium-dependent [3H] MTX uptake was determined
as the pooled standard deviation (SEM) and t-values were obtained using the
standardized mean difference (dt) to confirm significant differences in sodium-
dependentMTX uptake after pre-treatment with PB-type inducers, TCPOBOP or
modulators of phosphorylation in comparison with an untreated control. The
critical value of t was obtained from the t-table (two-sided test) and is a function
of p and df (tdf,p), where p=0.05 is the level of significance and df the degree of
freedom of the sample set.3. Results
3.1. Pretreatment of HPCT-1E3 cells with PB-type CYP450
inducers
To investigate the influence of phenobarbital (PB)-type
CYP450 inducers on Rfc1 activity, HPCT-1E3 cells were pre-
treated with therapeutic plasma concentrations of PB, carbama-
zepine (CBZ), chlorpromazine (CPZ) and chlortrimazole (CTZ)
as well as tenfold (threefold for CBZ) therapeutic plasma
concentrations over 48–60 h. Incubation with drugs used for the
same clinical indication lacking CYP450 inducing activity such
as diazepam, haloperidol or amphotericin B served as negative
controls. Cytotoxicity of the different substances was assessed
by the WST-1 proliferation test before initiation of the Rfc1
uptake assays. Viability remained >90% after incubation with
PB (IC50∼900 μg/ml), CBZ (IC50∼90 μg/ml), CPZ (IC50
∼4 μg/ml), CTZ (IC50∼6 μg/ml), amphotericin B (IC50>
150 μg/ml), haloperidol (IC50>3.5 μg/ml) and the lower con-
centration (1.5 μg/ml) of diazepam. Treatment with 15 μg/ml of
diazepam resulted in a reduction of HPCT-1E3 cell viability to
60% (IC50∼30 μg/ml).
In a second step, Rfc1 activity was measured as the sodium-
dependent accumulation of FMTX (10 μM) over 30 min as well
as time- and sodium-dependent uptake of [3H] MTX (5 μM)
over 20 min and calculated as the difference in MTX uptake in
the presence or absence of extracellular sodium (137 mM). Both
MTX analogues are, as previously shown, marker substrates of
RFC1/Rfc1 mediated uptake [10,15,21].
3.2. Effects of PB-type CYP450 inducers on FMTX uptake
In agreement with previously published data, sodium-
dependent FMTX uptake was 20–40 pmol/mg protein/30 min
in untreated HPCT-1E3 cells and accounted for 50–80% of total
FMTX accumulation [12,15,21]. Pre-treatment of cell cultures
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concentrations of PB, CBZ, CPZ resulted in a significant
reduction of sodium-dependent FMTX uptake by 42 and 77%
(p<0.001), 23 and 52% (p<0.05), 50 and 84% (p<0.001) or 82
and 83% (p<0.001), respectively. There was no alteration in the
sodium-independent FMTXaccumulation. In contrast, incubation
of HPCT-1E3 cells with the respective control substances
diazepam, haloperidol or amphotericin B did not lead to changes
in Rfc1 mediated and sodium-independent FMTX accumulation.
3.3. Effects of PB-type CYP450 inducers on [3H] MTX uptake
Rfc1 mediated [3H] MTX uptake rapidly reached a plateau
level in untreated hepatocytoma cells after an initial uptake
interval over 3 min (Fig. 1A and B). Sodium-dependent [3H]
MTX uptake over 20 min corresponded to 3.5 times the cell
surface-bound MTX at t=0.25 min. The proportion of thisFig. 1. Decrease of Rfc1 uptake activity after pre-treatment with PB and
TCPOBOP. HPCT-1E3 cells were treated with therapeutic and 10X therapeutic
concentrations of PB (A) as well as with 0.1 and 1 ng/ml of the direct CAR-
agonist TCPOBOP (B) for 48 h. Cells were harvested and the culture medium
was replaced by Tyrode buffer or sodium-free Choline-Tyrode buffer and 5 μM
MTX containing 2×105 dpm [3H] MTX was added. Uptake was stopped by
centrifugation of aliquots through a silicon oil cushion and the incorporated
radioactivity was measured by liquid scintillation counting. Rfc1 activity was
defined as the sodium- and time-dependent uptake of MTX (5 μM) over 20 min.
Values are mean±SEM (*p<0.05, **p<0.01, ***p<0.001, n=4).membrane binding was discounted in all further calculations.
Only the sodium-dependent uptake rate during the initial uptake
interval and the total sodium-dependent accumulation of MTX
in HPCT-1E3 cells at the plateau level were used as criteria of
Rfc1 activity. As shown representatively for PB (Fig. 1A), Rfc1
mediated MTX influx within the initial uptake interval was
decreased after pre-treatment with 10 and 100 μg/ml PB (by
approximately 80%; p<0.001) relative to untreated controls.
Similar results were obtained by pre-treatment with 3 and 9 μg/
ml CBZ (80%; p<0.01), 0.035 μg/ml CPZ (60%; p<0.01),
0.35 μg/ml CPZ (40%; p<0.001), 0.034 μg/ml CTZ (60%;
p<0.05) or 0.34 μg/ml CTZ (60%; p<0.01) (see also
Supplemental data Figs. 1, 2 and 3). The fraction of the cellular
MTX content at the plateau level accounted to Rfc1 mediated
uptake was also reduced by pre-treatment with 10 and 100 μg/
ml PB (by approximately 75%; p<0.001) compared with
untreated controls. Same results were obtained by incubation of
cells with 3 and 9 μg/ml CBZ (60%; p<0.01), 0.035 μg/ml CPZ
(70%; p<0.01), 0.35 μg/ml CPZ (75%; p<0.001), 0.034 μg/ml
CTZ (80%; p<0.05) or 0.34 μg/ml CTZ (70%; p<0.01). The
sodium-independent accumulation of the drug was unaffected.
Incubation of cells with 15 μg/ml diazepam, which is not a
CYP450 inducer, but not with therapeutic plasma concentra-
tions (1.5 μg/ml) of this control substance resulted in a slight
reduction in sodium-dependent [3H] MTX accumulation which
was only significant at the plateau level (see Supplemental data
Fig. 4) and may be attributed to cytotoxic effects of the drug.
3.4. Effect of the CAR-agonist TCPOBOP on [3H] MTX uptake
To investigate the involvement of the CAR receptor in the
regulation of Rfc1 activity, hepatocytoma cells were pre-treated
with the CAR agonist TCPOBOP. Cytotoxicity of the herbicide
derivative was excluded (IC50>20 μg/ml) by means of the
WST-1 proliferation test before initiation of the Rfc1 uptake
assays. As illustrated in Fig. 1B, Rfc1 mediated [3H] MTX
uptake within the initial uptake interval as well as at the plateau
level was decreased by 85 and 90% after incubation of cells
with 0.1 ng/ml TCPOBOP (p<0.01) and by 70 and 80% after
incubation with 1 ng/ml (p<0.01). The sodium-independent
substrate accumulation was unaffected.
3.5. Effects of PB and diazepam on Rfc1 reporter gene activity
In order to investigate the effects of the CYP inducers on the
expression of secreted alkaline phosphatase as reporter gene
under control of the likely hepatic promoter region of rat Rfc1, a
suitable plasmid was constructed. It contained the noncoding
exon1 transcribed in kidney, the sequence termed intron1 which
directly precedes noncoding exon1a expressed in the liver [23],
as well as exon1a itself which carries the predicted barbiturate
response element [10]. This plasmid was transfected in MDCK
kidney epithelial cells, Cos-1 fibroblasts as well as HPCT-1E3
cells, and transfected cells were incubated for 24 h with 30 and
100μg/ml PB, 15μg/ml diazepam, 41μg/ml rifampicin, 0.62μg/
ml PMA and 100 ng/ml lipopolysaccharide. SEAP activities in
the culture supernatants of the untreated but transfected controls
Fig. 3. Effect of PB, TCPOBOP and diazepam on Rfc1 protein levels. HPCT-
1E3 cells were seeded onto 96 well plates and incubated in culture medium (C)
supplemented with 10 (a) or 100 (b) μg/ml PB, 1.5 (e) or 15 (f) μg/ml diazepam
as well as with 0.1 (c) or 1 ng/ml (d) TCPOBOP for 12, 24 and 48 h. Expression
levels of Rfc1 protein were analysed by quantitative immunocytochemistry
using a specific Rfc1 antiserum. Control incubations included omission of
secondary and/or primary antibody. Total cell protein content was measured
using the BCA protein assay and relative Rfc1 protein levels were expressed
relatively to the control level as % extinction per mg of total protein. Values are
mean±SD (n=6).
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of the above treatments significantly induced or reduced reporter
gene expression in any of the three models.
3.6. Impact of PB and TCPOBOP on Rfc1 gene expression
To determine whether reduction of Rfc1 uptake activity by
PB-type CYP450 inducers and CAR agonist TCPOBOP is
associated with decreased Rfc1 mRNA levels, Rfc1 transcript
levels were measured by quantitative RT-PCR. The amount of
Rfc1 mRNA was normalized to the level of β-actin. As
illustrated in Fig. 2, neither treatment of HPCT-1E3 cells with
100 μg/ml PB nor incubation with 1 ng/ml TCPOBOP over 12,
24 or 48 h resulted in a significant alteration in relative Rfc1
gene expression compared with the untreated control.
3.7. Effects of PB, TCPOBOP and diazepam on the Rfc1
protein amount
In a further series of experiments on the regulatory
mechanism of Rfc1 activity, we measured the effect of PB,
TCPOBOP or diazepam pre-treatment on Rfc1 protein levels by
quantitative immunocytochemistry. As shown in Fig. 3,
treatment of cells with the selected substances over 12 to 48 h
did not cause a significant alteration in Rfc1 protein levels
normalized to the overall cell protein content. Incubation of
cells with 15 μg/ml diazepam over 48 h resulted in a decrease of
relative Rfc1 protein levels of about 25% probably associated
with drug toxicity. However, this reduction relative to untreated
cells remained statistically insignificant.
3.8. Downregulation of Rfc1 mediated MTX uptake by okadaic
acid and PMA
In addition to the regulation of gene expression, post-
translational phosphorylation of carrier proteins representsFig. 2. Effect of PB and TCPOBOP on Rfc1 gene expression. HPCT-1E3 cells
were treated with 100 μg/ml PB and 1 ng/ml TCPOBOP for 12, 24 and 48 h. Rfc1
transcript levels were analysed by quantitative RT-PCR using 1 μg of total RNA
and rat gene specific Rfc1 primers and probes as described under Materials and
methods. Relative Rfc1 mRNA levels were expressed as the percentage of the
Rfc1 gene expression comparatively to the control level. β-actin was used as an
internal standard. The data represent the mean±SD of two different measure-
ments in which quadruplicates were obtained.another important regulatory mechanism [24]. Previously, we
and others have shown that human as well as rodent RFC1/
Rfc1 possess putative PKC phosphorylation sites [10,25].
Similar to PB-type CYP450 inducers, short-term treatment
(2 h) with established concentrations of the PP 1/2A inhibitor
okadaic acid or the PKC inducer PMA [26] resulted in a
significant reduction in Rfc1 mediated MTX influx by on
average 65% (p<0.01%) or 75% (p<0.001%), respectively
(Fig. 4A). Moreover, Rfc1 uptake activity was almost
completely abolished after simultaneous incubation with
both modulators (p<0.001%). As for PB-type CYP450
inducers, this pre-treatment did not lead to a significant
alteration in the sodium-independent MTX accumulation.
To investigate whether suppression of Rfc1 activity was due
to specific activation of PKC, cells were incubated with PMA
and/or the specific PKC inhibitor BIM [27] simultaneously over
2 h before initiation of uptake assays. As illustrated in Fig. 4B,
repression of Rfc1 mediated MTX uptake by PMAwas reversed
to 50–70% after concurrent incubation with BIM. Exclusive
treatment of cells with the specific PKC inhibitor had no effect
on Rfc1 activity (Fig. 4B). Sodium-independent accumulation
of the marker substrate was again not affected by PMA and/or
BIM treatment.
3.9. Effects of cAMP or H-89 on Rfc1 activity
To investigate whether Rfc1 activity is also affected by PKA,
hepatocytoma cells were incubated with established concentra-
tions of the PKA inducer cAMP [28] and/or the specific PKA
inhibitor H-89 [29] over 2 h. In contrast to PKC, specific
activation of PKA was not related to a decrease in Rfc1
mediated and sodium-independent MTX uptake (see Supple-
mental data Fig. 5). These results so far suggest that Rfc1 uptake
activity in HPCT-1E3 cells is regulated on the posttranscrip-
tional level by PP 1/2A and PKC but not PKA.
Fig. 5. Reversal of PB and TCPOBOP mediated reduction of Rfc1 transport
activity by short-term treatment with PKC inhibitor BIM. HPCT-1E3 cells
were pre-treated with 100 μg/ml PB (A) or 1 ng/ml TCPOBOP (B) for 48 h
before the specific PKC inhibitor BIM (21 ng/ml) was added for 2 h. Cells
were harvested and the culture medium was replaced by Tyrode buffer or
sodium-free Choline-Tyrode buffer and 5 μM MTX containing 2×105 dpm
[3H] MTX was added. Uptake was stopped by centrifugation of aliquots
through a silicon oil cushion and the incorporated radioactivity was measured
by liquid scintillation counting. Rfc1 activity was defined as the sodium- and
time-dependent uptake of MTX (5 μM) over 20 min. The data represent
the mean±SEM of quadruplicate measurements (*p<0.05, **p<0.01,
***p<0.001).
Fig. 4. Effect of PKC inducer PMA, PKC inhibitor BIM and PP 1/2A inhibitor
okadaic acid on Rfc1 transport activity. HPCT-1E3 cells were pre-treated with
0.62 μg/ml PMA and/or 80.5 ng/ml OA (A) as well as with 0.62 μg/ml PMA
and/or 21 ng/ml BIM (B) over 2 h. Cells were harvested and the culture
medium was replaced by Tyrode buffer or sodium-free Choline-Tyrode buffer
and 5 μM MTX containing 2×105 dpm [3H] MTX was added. Uptake was
stopped by centrifugation of aliquots through a silicon oil cushion and the
incorporated radioactivity was measured by liquid scintillation counting. Rfc1
activity was defined as the sodium- and time-dependent uptake of MTX (5 μM)
over 20 min. Values are mean±SEM (*p<0.05, **p<0.01, ***p<0.001,
n=4).
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reduction of Rfc1 uptake activity
As described above, a similar pattern of Rfc1 repression
was observed with PB-type CYP450 inducers, the CAR
agonist TCPOBOP and modulators of phosphorylation.
Therefore, we aimed to determine the involvement of PKC
in regulation of Rfc1 activity by these CYP450 inducers by
examining the potential effect of the specific PKC inhibitor
BIM on reduction of Rfc1 mediated MTX uptake by PB or
TCPOBOP. Incubation of cells with 100 μg/ml PB or 1 ng/ml
TCPOBOP over 48 h was associated with a significant
decrease in the Rfc1 mediated MTX influx (Fig. 5A and B)
but not with the sodium-independent accumulation of the
drug. This inhibition was almost completely reversed by
concurrent treatment of cells (2 h) with BIM. Addition of the
PKC inhibitor alone did not result in a significant alteration ofRfc1 activity in comparison with an untreated control. Cells
incubated with PMA and/or BIM served as a positive control
(see also Fig. 4B).
Finally, the MTX influx rate (Vinflux) which, if substrate
affinity is unchanged, is directly proportional to the number of
active transport proteins was determined. As shown in Table 1,
the Rfc1 mediated MTX influx rate over 20 min was decreased
after pre-treatment of cells with PB or TCPOBOP over 48 h as
well as with PMA for 2 h (left panel) while the sodium-
independent accumulation rate was generally not affected (right
panel). Moreover, the reduction of the sodium-dependent MTX
Table 1
Effect of PB-type CYP450 inducers and modulators of PKC activity on sodium-
dependent, Rfc1 mediated and sodium-independent MTX uptake rate (Vinflux) in
HPCT-1E3 cells
Na+-dependent
MTX influx rate (Vi)
Na+-independent
MTX influx rate (Vi)
Control 6.51±0.46 4.24±0.77
+100 μg/ml PB 4.29±0.45⁎ 4.07±0.58
+100 μg/ml PB } 6.42±1.58 3.93±0.61
+21 μg/ml BIM
+0.62 μg/PMA 3.32±0.42⁎ 5.10±0.46
+0.62 μg/ml PMA } 6.09±0.50 4.44±0.32
+21 ng/ml BIM
Control 2.40±0.38 6.44±0.58
+1 ng/ml TCPOBOP 0.18±0.65⁎⁎ 6.75±1.06
+1 ng/ml TCPOBOP } 3.02±0.51 6.43±0.79
+21 ng/ml BIM
+0.62 μg/ml PMA 0±0.39⁎ 7.57±0.67
+0.62 μg/ml PMA } 1.69±0.38 6.59±0.48
+21 ng/ml BIM
Cells were pre-treated with PB or TCPOBOP for 48 h as well as PMA and/or
BIM over 2 h. Consecutively, the sodium-dependent or sodium-independent
uptake rate of the drug over 20 min was determined and expressed in pmol/mg
protein/min. The results represent the mean±SEM of at least triplicate
measurements.
⁎ p<0.001.
⁎⁎ p<0.01.
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PKC inhibitor BIM.
4. Discussion
RFC1/Rfc1 mediated transport of folates and antifolate drugs
such as methotrexate (MTX) is essential for cell metabolism
[1,3] and the clinical efficacy of cancer chemotherapy [2].
Interestingly, clinical studies suggest that concurrent long-term
anticonvulsant therapy of ALL or HGG patients with PB or
CBZ may cause a decrease in intracellular MTX levels
associated with a reduced efficacy of cancer chemotherapy
and, accordingly an aggravated prognosis [17,18]. However, the
molecular mechanism of the reduction of the intracellular MTX
content has not yet been elucidated. It could not be attributed to
CYP450 enzyme induction, as metabolism of MTX is mediated
by hepatocellular aldehyde oxidase and folylpolyglutamate
synthetase [4]. Co-medication with anticonvulsants is frequent
as seizures are a common complication in cancer patients [30].
In this study, we have therefore systematically investigated, for
the first time, the issue of Rfc1 regulation by PB-type CYP450
inducers on the functional, transcriptional, and translational
level.
Important characteristics of MTX and FMTX transport in the
HPCT-1E3 in vitro model such as sodium-dependency at
neutral pH and the rate of accumulation were in agreement with
previous studies in liver cell lines and primary rat hepatocytes
[1,13,15,21]. In addition to Rfc1, the sodium-independent
import carrier organic anion transporter2 (Oat2, Slc22a7) and
the efflux carrier Mrp1 (Abcc1), Mrp2 (Abcc2), Mrp3 (Abcc3)
as well as Mrp4 (Abcc4) are involved in hepatocellular transportof MTX in rat [31,32]. These membrane proteins are also
endogenously expressed in HPCT-1E3 cells [21]. In spite of this
relatively complex circumstance, the sodium-dependent Rfc1
mediated [3H] MTX and FMTX uptake was reliably distin-
guished from sodium-independent Oat2 activity, as intracellular
substrate accumulation was measured in presence and absence
of extracellular sodium. Moreover, [3H] MTX uptake was
determined over 20 min and the initial uptake velocity (Vinflux)
was calculated by non-linear regression to exclude the influence
of Mrp mediated MTX elimination on the data.
As shown representatively for PB (Fig. 1A), our results
documented a reduction in functional Rfc1 transport activity
after pre-treatment with the PB-type CYP450 inducers PB,
CBZ, CPZ or CTZ. In all four cases, the initial velocity of
sodium-dependent [3H] MTX uptake was reduced. Addition-
ally, the fraction of the cellular MTX content at the plateau level
which was attributable to Rfc1 mediated uptake was also
diminished. Importantly, the downregulation of Rfc1 activity
was already observed after pre-treatment with therapeutic serum
levels of the PB-type inducers but not the control drugs
amphotericin B, diazepam and haloperidol. All effects noted
after incubation with 15 μg/ml diazepam (tenfold therapeutic
plasma concentration) were probably due to the cytotoxicity of
the drug which reduced cell viability to 60% in the WST-1 test
(IC50 ∼30 μg/ml).
Furthermore, it is unlikely that the observed reduction in
MTX uptake over 20 min was due to changes in sodium-
independent Oat2 influx or Mrp2/Mrp3 efflux activity because
there were no significant alterations in the sodium-independent
MTX accumulation. Moreover, an increased clearance by Mrp
results in decreased drug levels in the plateau phase but is
unlikely to affect the initial uptake velocity (0.25–3 min).
Phenobarbital, however, did clearly reduce initial uptake
velocity. To experimentally evaluate a potential contribution
of Mrp2/Mrp3 to MTX elimination in HPCT1E3 cells,
inhibition experiments using the Mrp1 inhibitor MK571
(50 μM) were performed [S. Halwachs, C. Kneuer and W.
Honscha, unpublished data]. Moderate changes in the kinetics
of MTX accumulation were only noted after 30 min. In
addition, previous studies showed stimulation of Mrp gene
expression only at high, non-therapeutic PB levels (200–
700 μg/ml [33,34]).
As it has been demonstrated that carrier proteins such as
Mrp2 can be regulated by nuclear receptor CAR [19], we have
further investigated the effect of the direct CAR agonist
TCPOBOP on MTX transport in HPCT-1E3 cells [20]. Our
results clearly suggest that the CAR signalling cascade is
involved in the regulation of Rfc1 activity (Fig. 1B). Although
direct evidence for binding of TCPOBOP to rat CAR is still
lacking, a ligand-dependent activation of CAR by TCPOBOP is
widely accepted on basis of studies on mouse CAR [35] and
reports of CYP2B induction by TCPOBOP in rat hepatocytes
[36].
In the context of the involvement of CAR in Rfc1
downregulation, it was unexpected that relative Rfc1 gene
expression was not significantly reduced after PB and
TCPOBOP treatment over 12, 24 and 48 h (Fig. 2). This result
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reporter gene study. The later showed that expression of alkaline
phosphatase under control of the likely liver promoter region of
rat rfc1 [10,23] encompassing exon1 (not transcribed in liver),
intron1 and exon1a (first non-coding exon of liver mRNA
which carries the predicted barbiturate response element) was
not altered by PB in MDCK, Cos-1 nor HPCT-1E3 cells.
Similarly, long-term treatment of human ovarian carcinoma
cells (SKOV-3) with 50 and 100 μg/ml CBZ resulted in a
significant reduction of Rfc mediated MTX uptake, but was not
associated with decreased gene expression levels [37]. This lack
of response on the gene expression level may be explained by
the absence of the CAR response element “phenobarbital
response enhancer module (PBREM)” involved in induction of
CYP 450 enzymes by PB and TCPOBOP [16] from the rfc1
gene 5′-flanking region [10].
In addition to regulation of gene expression, regulation of
protein levels is known to affect membrane transporters such as
Mrp2 [38]. However, there was no significant alteration in
relative Rfc1 protein levels after incubation of HPCT-1E3 cells
with various concentrations of PB, TCPOBOP compared to
controls (Fig. 3).
Other studies indicated that rapid phosphorylation represents
an important regulatory mechanism of transport proteins
such as Oat1 (Slc22a6) and Oatp1a4 (Slco1a4) of rat [26,27].
We therefore investigated the possible involvement of protein
kinase A and C as well as protein phosphatase 1/2A in the
regulation of Rfc1 dependent MTX uptake in HPCT-1E3 cells.
Our results demonstrated that PMA mediated induction of
PKC (Fig. 4A and B) as well as inhibition of protein phos-
phatase by OA (Fig. 4A) caused a significant reduction of Rfc1
activity within 2 h. Pre-treatment with both modulators had a
synergistic effect on Rfc1 dependent drug influx (Fig. 4A)
suggesting that Rfc1 uptake activity is under the regulation of
PKC and PP 1/2A. In contrast, PKA dependent regulatory
pathways did not affect sodium-dependent MTX uptake in
hepatocytoma cells. Interestingly, recent studies on the post-
transcriptional regulation of human RFC1 indicate a reduction
in intestinal folic acid uptake over 5 min in IEC-6 cells by PKA
inducer cAMP (50, 100 μM) at pH 5.5 [39]. Nabokina et al.
(2004) provided evidence for a decrease in RFC1 mediated folic
acid transport after incubation with cAMP (100 μM, 1 h) in a
human pancreatic cell line at pH 5.0. However the specific PKA
inhibitor H-89 (50–100 μM) failed to affect RFC1 [39,40].
Moreover, in both studies activation or inhibition of PKC by
PMA (10 μM) or BIM (10 μM), respectively, did not affect
RFC1 uptake activity. The cause of this interesting discrep-
ancy between these and our present study regarding the effect
of PKA and PKC modulators remains unresolved. It may,
potentially, be due to the different functional RFC/Rfc char-
acteristics at acidic versus neutral pH [15] or simply reflect
differences in the regulatory pathways between the three cell
types.
Finally, our data further confirm a central role of PKC in PB
and TCPOBOP induced reduction of Rfc1 uptake. The
downregulation of sodium-dependent MTX influx was almost
completely reversed by addition of the specific PKC inhibitorBIM during the final 2 h of incubation (Table 1, Fig. 5A and B).
We therefore speculate that PB dependent CAR activation
causes an increase in PKC activity leading to changes in kinase
and/or phosphatase activities which in turn cause inactivation of
the Rfc1 protein or an unidentified co-factor. This hypothesis is
supported by the observation that the phosphatase inhibitor OA
also led to a reduction of Rfc1 transport activity and acted
synergistically with PMA, presumably by preventing depho-
sphorylation and thereby carrier (or co-factor) activation (Fig.
4A). In this context it is noteworthy, that two putative PKC
binding sites have been predicted in Rfc1 [10].
In conclusion, this study demonstrated for the first time that
PB-type CYP450 inducers cause a marked reduction in
hepatocellular Rfc1 activity by a mechanism linked to the
constitutive androstane receptor and protein kinase C. Because
of the vital role of Rfc1 in folate and antifolate uptake and its
wide tissue distribution, downregulation of Rfc1 activity by
these inducers may result in functional folate deficiency and
alteration of total MTX pharmacokinetics. Our data also
provides an explanation for the reduced clinical efficacy of
MTX cancer chemotherapy when combined with PB-type
CYP450 inducing agents such as the antiepileptic drugs PB and
CBZ [17]. Careful consideration of this new type of
pharmacokinetic interaction characterised by deregulation of
essential transport pathways may help to further improve drug
therapy.
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